{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:07:32Z","timestamp":1790755652717,"version":"4.1.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,15]],"date-time":"2020-11-15T00:00:00Z","timestamp":1605398400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006093","name":"Patient-Centered Outcomes Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006093","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007904","name":"Texas A and M University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007904","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007914","name":"University of Texas Southwestern Medical Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007914","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008087","name":"Guthy-Jackson Charitable Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008087","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["206411\/Z\/17\/Z"],"award-info":[{"award-number":["206411\/Z\/17\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP110051"],"award-info":[{"award-number":["RP110051"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000890","name":"National Multiple Sclerosis Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000890","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.ymthe.2020.11.017","type":"journal-article","created":{"date-parts":[[2020,11,16]],"date-time":"2020-11-16T21:06:42Z","timestamp":1605560802000},"page":"1312-1323","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Selective Depletion of Antigen-Specific Antibodies for the Treatment of Demyelinating Disease"],"prefix":"10.1016","volume":"29","author":[{"given":"Wei","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka","family":"Khare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilip K.","family":"Challa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin M.","family":"Greenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raimund J.","family":"Ober","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3232-7238","authenticated-orcid":false,"given":"E. Sally","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2020.11.017_bib1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41572-018-0027-2","article-title":"Immune-mediated neuropathies","volume":"4","author":"Kieseier","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.ymthe.2020.11.017_bib2","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41582-018-0112-x","article-title":"Myelin oligodendrocyte glycoprotein antibodies in neurological disease","volume":"15","author":"Reindl","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.ymthe.2020.11.017_bib3","doi-asserted-by":"crossref","first-page":"603","DOI":"10.3389\/fimmu.2017.00603","article-title":"Mechanisms of autoantibody-induced pathology","volume":"8","author":"Ludwig","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2020.11.017_bib4","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.tmrv.2013.05.004","article-title":"Adverse effects of human immunoglobulin therapy","volume":"27","author":"Stiehm","year":"2013","journal-title":"Transfus. Med. Rev."},{"key":"10.1016\/j.ymthe.2020.11.017_bib5","doi-asserted-by":"crossref","first-page":"e184169","DOI":"10.1001\/jamanetworkopen.2018.4169","article-title":"Association of immunoglobulin levels, infectious risk, and mortality with rituximab and hypogammaglobulinemia","volume":"1","author":"Barmettler","year":"2018","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.ymthe.2020.11.017_bib6","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1053\/j.seminhematol.2010.01.002","article-title":"Rituximab-associated infections","volume":"47","author":"Gea-Banacloche","year":"2010","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.ymthe.2020.11.017_bib7","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1001\/archneur.63.7.930","article-title":"Plasma exchange in neuroimmunological disorders: Part 1: Rationale and treatment of inflammatory central nervous system disorders","volume":"63","author":"Lehmann","year":"2006","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.ymthe.2020.11.017_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1471-4159.1999.0720001.x","article-title":"The structure and function of myelin oligodendrocyte glycoprotein","volume":"72","author":"Johns","year":"1999","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.ymthe.2020.11.017_bib9","doi-asserted-by":"crossref","first-page":"e89","DOI":"10.1212\/NXI.0000000000000089","article-title":"MOG cell-based assay detects non-MS patients with inflammatory neurologic disease","volume":"2","author":"Waters","year":"2015","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.ymthe.2020.11.017_bib10","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1001\/jamaneurol.2017.4601","article-title":"Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"75","author":"Hacohen","year":"2018","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.ymthe.2020.11.017_bib11","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/s41583-019-0233-2","article-title":"B cells in autoimmune and neurodegenerative central nervous system diseases","volume":"20","author":"Sabatino","year":"2019","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.ymthe.2020.11.017_bib12","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1177\/1352458519845112","article-title":"The clinical spectrum and incidence of anti-MOG-associated acquired demyelinating syndromes in children and adults","volume":"26","author":"de Mol","year":"2020","journal-title":"Mult. Scler."},{"key":"10.1016\/j.ymthe.2020.11.017_bib13","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1002\/1521-4141(200207)32:7<1905::AID-IMMU1905>3.0.CO;2-L","article-title":"Critical role of antigen-specific antibody in experimental autoimmune encephalomyelitis induced by recombinant myelin oligodendrocyte glycoprotein","volume":"32","author":"Lyons","year":"2002","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.ymthe.2020.11.017_bib14","doi-asserted-by":"crossref","first-page":"462","DOI":"10.4049\/jimmunol.171.1.462","article-title":"Rat and human myelin oligodendrocyte glycoproteins induce experimental autoimmune encephalomyelitis by different mechanisms in C57BL\/6 mice","volume":"171","author":"Oliver","year":"2003","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2020.11.017_bib15","doi-asserted-by":"crossref","first-page":"8207","DOI":"10.1073\/pnas.122092499","article-title":"Molecular characterization of antibody specificities against myelin\/oligodendrocyte glycoprotein in autoimmune demyelination","volume":"99","author":"von B\u00fcdingen","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2020.11.017_bib16","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.1172\/JCI118368","article-title":"Antibody facilitation of multiple sclerosis-like lesions in a nonhuman primate","volume":"96","author":"Genain","year":"1995","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2020.11.017_bib17","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jaut.2017.09.002","article-title":"Myelin oligodendrocyte glycoprotein-specific antibodies from multiple sclerosis patients exacerbate disease in a humanized mouse model","volume":"86","author":"Khare","year":"2018","journal-title":"J.\u00a0Autoimmun."},{"key":"10.1016\/j.ymthe.2020.11.017_bib18","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1172\/JCI28334","article-title":"Myelin oligodendrocyte glycoprotein-specific T and B cells cooperate to induce a Devic-like disease in mice","volume":"116","author":"Bettelli","year":"2006","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2020.11.017_bib19","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1084\/jem.20090299","article-title":"Spontaneous relapsing-remitting EAE in the SJL\/J mouse: MOG-reactive transgenic T\u00a0cells recruit endogenous MOG-specific B cells","volume":"206","author":"P\u00f6llinger","year":"2009","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.ymthe.2020.11.017_bib20","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/nm1488","article-title":"Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein","volume":"13","author":"O\u2019Connor","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2020.11.017_bib21","doi-asserted-by":"crossref","first-page":"102399","DOI":"10.1016\/j.msard.2020.102399","article-title":"Clinical and laboratory features distinguishing MOG antibody disease from multiple sclerosis and AQP4 antibody-positive neuromyelitis optica","volume":"45","author":"Ciotti","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.ymthe.2020.11.017_bib22","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/ana.25291","article-title":"Pathogenicity of human antibodies against myelin oligodendrocyte glycoprotein","volume":"84","author":"Spadaro","year":"2018","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ymthe.2020.11.017_bib23","first-page":"901","article-title":"Pathology of multiple sclerosis: where do we stand?","volume":"19","author":"Popescu","year":"2013","journal-title":"Continuum (Minneap. Minn.)"},{"key":"10.1016\/j.ymthe.2020.11.017_bib24","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1073\/pnas.1519608113","article-title":"Autoantibody-boosted T-cell reactivation in the target organ triggers manifestation of autoimmune CNS disease","volume":"113","author":"Flach","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2020.11.017_bib25","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s00401-016-1559-8","article-title":"Myelin-reactive antibodies initiate T\u00a0cell-mediated CNS autoimmune disease by opsonization of endogenous antigen","volume":"132","author":"Kinzel","year":"2016","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.ymthe.2020.11.017_bib26","doi-asserted-by":"crossref","first-page":"15314","DOI":"10.1038\/ncomms15314","article-title":"Engineered clearing agents for the selective depletion of antigen-specific antibodies","volume":"8","author":"Devanaboyina","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2020.11.017_bib27","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1038\/nbt1143","article-title":"Engineering the Fc region of immunoglobulin G to modulate in\u00a0vivo antibody levels","volume":"23","author":"Vaccaro","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2020.11.017_bib28","doi-asserted-by":"crossref","first-page":"eaan1208","DOI":"10.1126\/scitranslmed.aan1208","article-title":"The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: A randomized phase 1 study","volume":"9","author":"Kiessling","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2020.11.017_bib29","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1172\/JCI97911","article-title":"Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans","volume":"128","author":"Ulrichts","year":"2018","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2020.11.017_bib30","doi-asserted-by":"crossref","first-page":"176","DOI":"10.3389\/fimmu.2015.00176","article-title":"Fully human monoclonal antibody inhibitors of the neonatal Fc receptor reduce circulating IgG in non-human primates","volume":"6","author":"Nixon","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2020.11.017_bib31","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.jaci.2011.11.029","article-title":"Reduction of total IgE by targeted coengagement of IgE B-cell receptor and Fc\u03b3RIIb with Fc-engineered antibody","volume":"129","author":"Chu","year":"2012","journal-title":"J.\u00a0Allergy Clin. Immunol."},{"key":"10.1016\/j.ymthe.2020.11.017_bib32","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nbt0798-677","article-title":"An efficient route to human bispecific IgG","volume":"16","author":"Merchant","year":"1998","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2020.11.017_bib33","doi-asserted-by":"crossref","first-page":"546","DOI":"10.4161\/mabs.3.6.18123","article-title":"A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens","volume":"3","author":"Moore","year":"2011","journal-title":"MAbs"},{"key":"10.1016\/j.ymthe.2020.11.017_bib34","doi-asserted-by":"crossref","first-page":"19637","DOI":"10.1074\/jbc.M110.117382","article-title":"Enhancing antibody Fc heterodimer formation through electrostatic steering effects: applications to bispecific molecules and monovalent IgG","volume":"285","author":"Gunasekaran","year":"2010","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ymthe.2020.11.017_bib35","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/0165-5728(84)90064-X","article-title":"A novel myelin-associated glycoprotein defined by a mouse monoclonal antibody","volume":"6","author":"Linnington","year":"1984","journal-title":"J.\u00a0Neuroimmunol."},{"key":"10.1016\/j.ymthe.2020.11.017_bib36","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1158\/1535-7163.MCT-17-0092","article-title":"Targeting phosphatidylserine with calcium-dependent protein-drug conjugates for the treatment of cancer","volume":"17","author":"Li","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ymthe.2020.11.017_bib37","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1126\/science.1152066","article-title":"Membrane phosphatidylserine regulates surface charge and protein localization","volume":"319","author":"Yeung","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2020.11.017_bib38","doi-asserted-by":"crossref","first-page":"6181","DOI":"10.1073\/pnas.1203954109","article-title":"Mouse model recapitulating human Fc\u03b3 receptor structural and functional diversity","volume":"109","author":"Smith","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2020.11.017_bib39","doi-asserted-by":"crossref","first-page":"888","DOI":"10.3389\/fneur.2018.00888","article-title":"Diagnosis and treatment of NMO spectrum disorder and MOG-encephalomyelitis","volume":"9","author":"Borisow","year":"2018","journal-title":"Front. Neurol."},{"key":"10.1016\/j.ymthe.2020.11.017_bib40","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1212\/WNL.0000000000009758","article-title":"Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder","volume":"95","author":"Chen","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.ymthe.2020.11.017_bib41","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s40259-015-0133-6","article-title":"Fusion proteins for half-life extension of biologics as a strategy to make biobetters. BioDrugs: Clinical Immunotherapeutics","volume":"29","author":"Strohl","year":"2015","journal-title":"BioDrugs"},{"key":"10.1016\/j.ymthe.2020.11.017_bib42","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.3389\/fimmu.2017.01576","article-title":"From IgG fusion proteins to engineered-specific human regulatory T\u00a0cells: a life of tolerance","volume":"8","author":"Scott","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2020.11.017_bib43","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1182\/blood-2017-12-822908","article-title":"Tolerogenic properties of the Fc portion of IgG and its relevance to the treatment and management of hemophilia","volume":"131","author":"Blumberg","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2020.11.017_bib44","doi-asserted-by":"crossref","first-page":"5889","DOI":"10.1073\/pnas.0700337104","article-title":"Elucidation of intracellular recycling pathways leading to exocytosis of the Fc receptor, FcRn, by using multifocal plane microscopy","volume":"104","author":"Prabhat","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2020.11.017_bib45","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/cdd.2016.11","article-title":"Phosphatidylserine is a global immunosuppressive signal in efferocytosis, infectious disease, and cancer","volume":"23","author":"Birge","year":"2016","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.ymthe.2020.11.017_bib46","doi-asserted-by":"crossref","first-page":"19057","DOI":"10.1073\/pnas.0607242103","article-title":"Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis","volume":"103","author":"Zhou","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2020.11.017_bib47","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1146\/annurev-immunol-051116-052415","article-title":"Immune responses in the liver","volume":"36","author":"Kubes","year":"2018","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2020.11.017_bib48","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jhep.2010.10.005","article-title":"Liver antigen-presenting cells","volume":"54","author":"Crispe","year":"2011","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.ymthe.2020.11.017_bib49","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1080\/19420862.2019.1602459","article-title":"Neonatal Fc receptor expression in macrophages is indispensable for IgG homeostasis","volume":"11","author":"Challa","year":"2019","journal-title":"MAbs"},{"key":"10.1016\/j.ymthe.2020.11.017_bib50","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1146\/annurev-immunol-042617-053010","article-title":"Apoptosis and clearance of apoptotic cells","volume":"36","author":"Nagata","year":"2018","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2020.11.017_bib51","doi-asserted-by":"crossref","first-page":"19246","DOI":"10.1073\/pnas.1114799108","article-title":"Constitutive exposure of phosphatidylserine on viable cells","volume":"108","author":"Segawa","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2020.11.017_bib52","doi-asserted-by":"crossref","first-page":"655","DOI":"10.4161\/mabs.25439","article-title":"Autoantibody depletion ameliorates disease in murine experimental autoimmune encephalomyelitis","volume":"5","author":"Challa","year":"2013","journal-title":"MAbs"},{"key":"10.1016\/j.ymthe.2020.11.017_bib53","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1186\/s12974-020-01825-1","article-title":"Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 2: Results from 108 lumbar punctures in 80 pediatric patients","volume":"17","author":"Jarius","year":"2020","journal-title":"J.\u00a0Neuroinflammation"},{"key":"10.1016\/j.ymthe.2020.11.017_bib54","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1186\/s12974-020-01824-2","article-title":"Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1: Results from 163 lumbar punctures in 100 adult patients","volume":"17","author":"Jarius","year":"2020","journal-title":"J.\u00a0Neuroinflammation"},{"key":"10.1016\/j.ymthe.2020.11.017_bib55","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/0378-1119(89)90359-4","article-title":"Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension","volume":"77","author":"Horton","year":"1989","journal-title":"Gene"},{"key":"10.1016\/j.ymthe.2020.11.017_bib56","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.4049\/jimmunol.1300019","article-title":"The encephalitogenic, human myelin oligodendrocyte glycoprotein-induced antibody repertoire is directed toward multiple epitopes in C57BL\/6-immunized mice","volume":"191","author":"Bansal","year":"2013","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2020.11.017_bib57","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1073\/pnas.0810796106","article-title":"Conditional deletion of the MHC class I-related receptor FcRn reveals the sites of IgG homeostasis in mice","volume":"106","author":"Montoyo","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2020.11.017_bib58","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1109\/TITB.2010.2049024","article-title":"A software framework for the analysis of complex microscopy image data","volume":"14","author":"Chao","year":"2010","journal-title":"IEEE Trans. Inf. Technol. Biomed."},{"key":"10.1016\/j.ymthe.2020.11.017_bib59","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.2967\/jnumed.113.136481","article-title":"Use of Fc-engineered antibodies as clearing agents to increase contrast during PET","volume":"55","author":"Swiercz","year":"2014","journal-title":"J.\u00a0Nucl. Med."},{"key":"10.1016\/j.ymthe.2020.11.017_bib60","doi-asserted-by":"crossref","first-page":"134","DOI":"10.4049\/jimmunol.178.1.134","article-title":"Feedback regulation of murine autoimmunity via dominant anti-inflammatory effects of interferon gamma","volume":"178","author":"Minguela","year":"2007","journal-title":"J.\u00a0Immunol."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001620306158?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001620306158?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:58:58Z","timestamp":1761501538000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001620306158"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":60,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S1525001620306158"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2020.11.017","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Selective Depletion of Antigen-Specific Antibodies for the Treatment of Demyelinating Disease","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2020.11.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s).","name":"copyright","label":"Copyright"}]}}